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Pseudoenzymes are catalytically deficient variants of
enzymes that are represented in all major enzyme
families. Their regulatory functions in signalling
pathways are shedding new light on the non-catalytic
functions of active enzymes, and are suggesting new
ways to target cellular signalling mechanisms with
drugs.contain, within every enzyme family where we look, di-What is a pseudoenzyme?
A pseudoenzyme contains a protein domain with a fold
that resembles, or is predicted to resemble, a catalytically
active, conventional protein domain counterpart. How-
ever, the pseudoenzyme possesses vestigial or zero cata-
lytic activity owing to the absence of key catalytic amino
acids or motifs. Such proteins have been long acknowl-
edged to exist within proteomes and have also been
termed nonenyzmes [1]. In a sense, pseudoenzymes can
be considered to be ‘zombie’ versions of proteins: ‘un-
dead’ in the sense that they still perform important cel-
lular functions, but at the same time ‘dead’ since they
possess negligible enzymatic activity relative to their
catalytically active cousins.How are pseudoenzymes identified?
Initially, by sequence comparisons. As genomes began
to be sequenced, and the analytical tools of computa-
tional biology matured, accurate alignment and com-
parison of deduced amino acid sequences revealed
common ‘signatures’ that could be compared and
contrasted between all polypeptides. The major cell
signaling enzyme families led the way in this regard,
with early efforts using manual alignment generating* Correspondence: Patrick.eyers@liverpool.ac.uk; jamesm@wehi.edu.au
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enzyme families (for example amongst the protein
kinases [2]). These patterns often explain how an
enzyme works or is likely to be regulated [3, 4]. They
may include, for example, the presence of a metal-
binding motif or a conserved network of amino acids
that form a catalytic signature.
What has become apparent now that thousands and
thousands of genomes have been sequenced is that they
vergent examples of proteins that are clearly part of
large enzyme families but for which basic enzyme func-
tion (increasing the rate of a chemical reaction) is pre-
dicted to be lacking. These ‘dead’ enzymes have amino
acid sequence deviations from the catalytic residues of
counterparts that would be predicted to confer enzyme
function—or, in an experimentally ideal world, where
such function has been quantified biochemically. Thus,
classification of pseudoenzymes is easiest for enzyme do-
mains for which we have an accumulated knowledge of
catalytic mechanism.
Undoubtedly, however, many pseudoenzymes have
yet to be classed as such, and there are probably many
‘enzymes’ that are actually pseudoenzymes; we just
haven’t confirmed this yet experimentally. Notably,
because there are distinct sequence deviations that
might compromise a cousin enzyme’s catalytic activity
to generate a pseudoenzyme, predicting whether a pro-
tein is catalytically deficient simply from inspection of
its sequence, not to mention the complexities of subse-
quent experimental validation, remains an enormous
challenge.So what does it take to be confident you have
identified a pseudoenzyme?
The best studies of pseudoenzymes attempt to make
structure:function predictions and then test them using
structural biology, biochemical, cellular and organism-
based analysis. Areas of enzymology that have led this
endeavor include studies of the kinases (which in termsarticle is distributed under the terms of the Creative Commons Attribution 4.0
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phosphotransferase enzymes with specificity for either
small molecules or proteins [5]) and the vast numbers of
metabolic enzymes analysed over the course of biochem-
ical history. In an ideal study, comparative biochemical
analysis of each (pseudo)enzyme should occur, although
this is a very time-consuming process and rarely possible
in practice (what if no turnover is detected; have the
‘correct’ conditions, cofactors and substrates been tested;
what if there are no apparent catalytically active counter-
parts for comparison?).
How do catalytically inert enzymes impact on
signalling networks?
Because of the prejudice that focused attention on the
catalytic functions of enzymes in signalling pathways, for a
long time pseudoenzymes were considered to be dead—-
and therefore evolutionary remnants or bystanders in cell
signalling networks. Contrary to this view, however, pseu-
doenzymes have now emerged as crucial players operating
with an impressive diversity of mechanisms that we are
only beginning to understand. Explaining how pseudoen-
zymes fit into our current paradigms of cell signalling isFig. 1. Pseudoenzymes can allosterically regulate a partner protein’s cataly
which lacks a canonical Zn-binding motif (residues shown as sticks and lab
activity. BRCC36 binds Zn2+ (grey sphere) via the labelled residues (shown a
into a higher order “superdimer”, which is an active DUB. PDB accession 5C
tail’ and allosterically regulates the activation of the conventional protein ty
bind to a nucleotide (cyan) and a divalent cation (grey spheres), HER3 exhib
acid residue to an Asn at position 815 (yellow sticks). In contrast, EGFR cont
to phosphorylate substrates on tyrosine residues. PDB accession 4RIW [31].an important challenge and crucial to developing ‘systems’
models of signal transduction. We are now realizing that
enzymes that regulate signalling, such as kinases, phospha-
tases, proteases, GTPases, ubiquitin modifying enzymes,
acetylases and sulfotransferases, can have many functional
properties other than catalysis, and these can be shared by
conventional enzymes and their pseudoenzyme counter-
parts. For example, they can function as dynamic scaffolds
that nucleate signalling, or as competitors in canonical sig-
nalling pathways, or as direct modulators (activators or in-
hibitors) of enzymes [6]. Two examples of activation by
pseudoenzymes can be found in Fig. 1. Direct modulation
of this sort appears to be particularly important for
pseudokinases [7], which are amongst the best-studied
pseudoenzymes and the subject of research in the au-
thors’ laboratories.
How did pseudoenzymes evolve?
We await a formal analysis of pseudoenzyme evolution
but it is likely that pseudoenzymes evolved from enzyme
counterparts through gene duplication that created an op-
portunity for additional copies to diverge in sequence from
ancestral enzymes in the absence of selective pressure attic activity. a The pseudo-deubiquitinase (DUB), KIAA0157 (yellow),
elled), binds to the canonical DUB, BRCC36 (blue), to promote its DUB
s blue sticks). The KIAA0157–BRCC36 heterodimeric complex assembles
W3 [11]. b The pseudokinase domain of HER3 (yellow) binds ‘head-to-
rosine kinase EGFR (blue). While each domain can accommodate and
its defective catalytic activity owing to substitution of the catalytic Asp
ains conventional catalytic residues (blue sticks, labelled), which allow it
Cartoons were drawn using Pymol
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function. Thus, a conserved fold or scaffold can evolve new
‘pseudoenzyme’ functions by ‘repurposing’ a classic enzyme
fold because the selective pressure to maintain active site
geometry (to support a catalytic cycle of substrate binding,
transition state, catalysis and substrate release) is relieved.
We should not rule out, however, at least in some
cases, the formal possibility that enzymes may actually
have evolved from pseudoenzymes, and there are some
interesting examples of likely pseudoenzyme:enzyme
switches amongst the protein kinases [6].
Have all families of enzyme evolved
pseudoenzyme paralogs?
This is a good question, and very much in need of a
comprehensive bioinformatic analysis. However, in es-
sentially any family of enzymes for which we have a
basic understanding of the catalytic residues, we rarely
fail to find counterparts with deviations in catalytic resi-
dues for which we would subsequently predict a catalytic
deficit. On the other hand, it should be stressed that we
rarely have biochemical evidence that pseudoenzymes do
indeed lack catalytic activity, either because we do not
know what their physiological substrate would likely be or
because in-depth experimental examination is pending.
However, for several of the best-studied enzyme families
involved in signalling (protein kinases, phosphatases, deu-
biquitinases, proteases), well studied examples of pseu-
doenzymes occur throughout nature, with biochemical,Fig. 2. Pseudoenzymes can adopt multiple structural conformations, perm
domain of mouse MLKL was crystallised in an open (equivalent to catalytic
unusual helix that buttresses against, and shuns, the αC helix. Counterparts
E338), and the K219-interacting Q343 from the activation loop helix, are shown
MLKL pseudokinase domain crystallised in a distinct closed conformation which
MLKL has evolved to function as a catalytically inactive conformational switch. C
K331, E351) are shown as yellow sticks. The canonical αC helix glutamic acid (E25
interacts with K230, as is typical of active protein kinase structures. PDB accessio
binding by MLKL is mediated by different pseudoactive site determinants and t
to permit nucleotide binding, which might drive or inhibit a switch mechanism
in a) to induce cell death by necroptosis [14, 18]. Cartoons drawn using Pymolstructural and cellular experimental evidence existing to
back this up [6, 8–11].How do structural features of the original
enzymes suit new pseudoenzyme functions?
We have already mentioned that catalytically active en-
zymes can also serve important functions as modulators of
signalling through non-catalytic functions [12, 13]. This
leads us to believe that enzyme structures are predisposed
to mediating interactions with protein or metabolite ligands
and thus these folds are the ideal templates for nature to re-
purpose for entirely new functions (Figs. 1 and 2). While
pseudoenzymes typically arise from subtle deviations in
amino acid sequence relative to catalytically active counter-
parts, the extent and manner of the impact of these devia-
tions on the structure differs for each pseudoenzyme.
Again, we know most about the protein pseudokinases,
where widespread loss or occasional unconventional modes
of nucleotide binding have evolved in the absence of select-
ive pressure to maintain active site geometry for catalysis.
An example is the pseudokinase MLKL, illustrated in Fig. 2
[10, 14]. In turn, this creates a new scenario in which the
stable fold of a pseudoenyzme can be exploited for a new
biological function, such as mediating protein interactions
via an allosteric site or repurposing of the substrate binding
site to regulate the signalling output of a partner protein by
modulating its cellular localization, activation or catalytic
activity (e.g. [15, 16]).itting them to function as molecular switches. a The pseudokinase
ally inactive) conformation in which the activation loop adopted an
of the catalytic residues in conventional protein kinases (K219, N318,
as yellow sticks. PDB accession 4BTF [18]. b The structure of the human
resembles that of an active conventional protein kinase, suggesting that
ounterparts of the catalytic residues in conventional protein kinases (K230,
0), rather than the activation loop residue observed in the mouse structure,
n 4MWI [14]. Accompanying mutational analyses illustrated that nucleotide
hat K219 (mouse) and K230 (human) have evolved unexpected functions
that controls release of the MLKL four-helix bundle (4HB) domain (shown
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roles?
Structural and biochemical studies over the past decade
have allowed us to grasp a greater appreciation of the
many mechanisms by which pseudoenzymes can adapt
the conventional enzyme fold to mediate new functions.
For example, in the case of pseudophosphatases, the adap-
tion is thought to create a tight-binding ‘phosphate trap’
that prevents substrates (phosphorylated proteins) from
being dephosphorylated and/or shields this phosphory-
lated epitope from the cellular machinery [17]. This might
then prolong a signalling event or change the subcellular
distribution of the target protein, including networks of
proteins normally regulated by the pseudosubstrate [6].
For pseudokinases, there appears to be a rich vein of adap-
tive capacity. As described above, conserved deviations of
key residues within the active site appear to relieve select-
ive pressures on active site geometry [14, 18], allowing for
evolution of conformational changes and additional allo-
steric functions.
How do studies of pseudoenzymes shed light on
the mechanisms of active enzymes?
Recent studies support the idea that insights from stud-
ies of pseudoenzymes can provide a window into under-
standing the non-catalytic functions of conventional
enzymes [12, 13, 19]. On the whole, it is conformation
(rather than catalytic output) that is most critical for the
regulated activation and inactivation cycles that most en-
zymes undergo as part of homeostatic mechanisms. This
observation is echoed in studies of multiple pseudokinases,
which can be trapped in conformations synonymous with
either active or inactive versions of their catalytically active
kinase cousins (see, for example, [14, 18]; Fig. 2). Such
conformational changes can be promoted by, for example,
allosteric interactions with binding partners or post-
translational modifications such as phosphorylation. In
most cases we do not understand how these different con-
formations lend themselves to distinct functions, but their
existence is generally supportive of the emerging idea that
pseudoenzyme functions must also be controlled, suggest-
ing that the different conformations represent the ‘on/off ’
phases of a molecular switch (Fig. 2).
In addition, knowledge of catalytic mechanisms can be
obtained from studies of conventional enzymes and con-
firmation of mechanism can come from (pseudo)enzyme
comparisons. This is particularly apparent in the pseudo-
phosphatases, in which a solitary amino acid substitution
can restore the highly conserved Cys-based phosphatase
catalytic mechanism that is lost in the pseudophosphatase
[20]). By contrast it is comparatively difficult to turn pseu-
dokinases back into enzymatically active kinases, suggest-
ing that the evolutionary events exploited for their new
roles are too numerous to allow facile reversion to theenzyme-mediated mode of signalling of their ancestor.
Interestingly, we are learning from comparisons of signal-
ling pseudoenzymes and enzymes that catalytic output
from enzymes varies over many orders of magnitude and
that pseudoenzymes may also fine-tune the activity of en-
zyme interaction partners. This might dampen down cata-
lytic output when it is a potential liability, for example
where suppression of the catalytic activity of the canonical
tyrosine kinase domain of the Janus kinase (JAK) by the
neighbouring pseudokinase domain depresses proliferative
signalling that could otherwise be tumourigenic [21, 22].
Most enzymes are subject to many layers of regulation,
but as we have learned from oncogenic protein kinases
(for example BRAF), a single amino acid switch that locks
them into a ‘super enzyme’ mode can be lethal; thus, it
may be an evolutionary advantage that some types of
pseudoenzymes are not readily reactivated by reversion
mutations.
What are the known functions of
pseudoenzymes?
Their functions encompass major regulatory roles in all
areas of biology and across life from prokaryotes to eu-
karyotes. Although several reviews discuss pseudoen-
zymes in cell signalling [6–9], and we know most about the
pseudoenzymes that have evolved in the kinase and phos-
phatase families, this area is ripe for further exploration.
For example, in the tyrosine phosphatase family, multiple
human pseudophosphatase domains have evolved [23],
with a catalytically inert pseudophosphatase present in par-
allel within the same polypeptide alongside a canonical
phosphatase domain containing assayable catalytic activity.
This situation is also found in some pseudokinase domain-
containing proteins (for example Janus kinases; GCN2), in
which the pseudokinase domain is the key regulatory elem-
ent that controls the catalytic output through an adjacent
canonical kinase domain. Why has this arrangement of
pseudoenzyme and enzyme domains proved so popular?
The answer, somewhat surprisingly, remains unknown.
Which are the pseudoenzymes of most interest at
present?
It is hard to say currently where our research directions
should specifically be focused, since the field is so young,
and in reality, scientists are in desperate need of new
tools and technology to identify, classify, evaluate and
uncover the biology of the pseudoenzymes. However, it
might be particularly pertinent to study pseudoenzymes
in more primitive organisms since these may reveal an-
cestral roles that have been co-opted throughout evolu-
tion (see, for example, [1]). In addition, quite recent
findings demonstrating that both intracellular and extra-
cellular phosphorylation-dependent signalling can be
driven by pseudokinases and kinase co-operation are
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doenzymes in fine-tuning the output of catalytically ac-
tive enzymes [16, 24]. In our laboratories, we do of
course have our particular research favourites, and these
generally represent the analysis of specific human pseu-
dokinases. For example, we think that MLKL, which
controls necroptosis through a switch-like mechanism
[14, 18] and the Tribbles pseudokinases, which modulate
protein ubiquitination [15, 25], are of outstanding inter-
est as models for understanding basic signalling mecha-
nisms by pseudoenzymes. Both of these exemplify the
vast and varied manner in which pseudoenzymes can
modulate cell signalling outputs via roles in mediating
protein interactions, including nucleating and control-
ling the output from multiprotein signalling complexes.
Can pseudoenzymes be therapeutically targeted?
This is a really important question and the answer is al-
most certainly yes. Indeed, based on the direction of
pharma and some of the patent literature, it is certain
that scientists are attempting to target pseudoenzymes,
both knowingly and (thought provokingly) unknowingly.
The likely conservation of structural fold, and a reliance
on protein–protein interactions for outputs, mean that
pseudoenzymes might be targeted therapeutically in es-
sentially the same ways as other enzymes (see, for ex-
ample, [26–28]). Indeed, in the case of pseudokinases, it
was found that promiscuous inhibitors that target the
ATP-binding cleft of conventional protein kinases could
also bind the equivalent site in pseudokinases despite
most of the examined pseudokinases exhibiting no de-
tectable ATP-binding capacity [10]. The difference is
that pseudoenzymes are likely to have degraded active
sites, so that although many drug families might be re-
purposed to target pseudoenzymes, new programs of
drug discovery are urgently needed to specifically modu-
late them. The deviations in ‘pseudoactive’ site geometry
raise the attractive idea that pseudoenzymes might have
evolved distinct features that will enable their specific tar-
geting by small molecules in preference to their catalytic-
ally active cousins. Of particular interest in the field of
signalling is that of the >50 protein pseudokinases found
in vertebrates [7], half have already been implicated in one
disease or another [6]. This furnishes enough potential
drug candidates to keep pharma busy for years, and we
predict that the pseudophosphatase, pseudoprotease and
pseudo-deubiquitinase fields are also likely to rise to
pharmaceutical prominence over the next decade. One
prominent example of a promising pseudokinase drug tar-
get is the Janus kinase (JAK) family of pseudokinase do-
mains, which are master regulators of the catalytic output
of JAK-driven signalling pathways central to blood cell
function. Indeed, the V617F mutation in the JAK2 pseudo-
kinase domain is known to promote the catalytic activityof the adjacent tyrosine kinase domain [21, 29]. As a result,
this pseudokinase domain mutation is causative of the my-
eloproliferative neoplasm polycythemia vera, making this a
very exciting potential drug target [22].
What are the most important issues in the future
of pseudoenzyme research?
While we have made a lot of progress over the past
10 years, we still lack knowledge of the cellular functions
performed by most pseudoenzymes and their evolutionary
origins, including patterns of conservation across various
genomes. For some pseudoenzyme/enzyme families this
understanding is well on the way, but is potentially con-
founded by nature’s repurposing of distinct structural
folds, which are not always obvious from primary struc-
tures of proteins, especially for convergent functions [30].
Even within closely related pseudoenzymes families (such
as the three Tribbles pseudokinases, Trib1, Trib2 and
Trib3 and their obscure pseudokinase cousin, SgK495)
different biological and biochemical functions have been
attributed to each pseudoenzyme in mammals. This high-
lights a major challenge facing those in the field, which is
the necessity to study each and every pseudoenzyme in
detail, using structural biology, biochemistry, cell biology
and in vivo models, to deduce mechanism of action and
biological function. As more and more pseudoenzymes
are assigned functions in signalling pathways and become
foci for drug discovery, we predict that the suite of avail-
able tools and methodologies to rigorously interrogate
pseudoenzymes will coordinately grow, ensuring that the
community continues to expand and thrive.
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